

CROATIAN JOURNAL OF ONCOLOGY

LIBRI ONCOLOGICI

50
1972.-2022.



LIBRI ONCOL. ISSN 0300-8142
UDK 616 – 006

2022 Vol. 50 Suppl. 2

VOLUMEN 50

NUMERUS suppl 2

LIBRI ONCOLOGICI

CROATIAN JOURNAL OF ONCOLOGY

Zagreb, 2022

CROATIAN JOURNAL OF ONCOLOGY
LIBRI ONCOLOGICI

Publisher

Sestre milosrdnice University Hospital Center
University Hospital for Tumors, Zagreb, Croatia

Editor-in-Chief

Ivan Milas

Editors

Lidija Beketić-Orešković, Antonio Juretić, Božena Šarčević

Associate Editors

Iva Kirac – Experimental Research
Mladen Stanec – Surgical Oncology
Robert Šeparović – Medical Oncology
Petar Suton – Radiation Oncology

Technical Editor

Anica Vrdoljak

Editorial Board

Gordana Brozović, Željko Herceg, Ljiljana Mayer, Aleksandar Milenović, Mario Puljiz, Snježana Ramić, Vesna Ramljak, Andrej Roth, Sanda Šitić, Danko Velimir Vrdoljak, Tiha Vučemilo

Editorial Council

M. Ćorić (Zagreb, Croatia), T. Čufer (Ljubljana, Slovenia), N. Đaković (Zagreb, Croatia), G. Fisher (Stanford, USA), M. Gamulin (Zagreb, Croatia), D. Kalafatić (Zagreb, Croatia), S. Kaštelan (Zagreb, Croatia), Ž. Kaštelan (Zagreb, Croatia), M. Klarica (Zagreb, Croatia), D. Krleža (Dublin, Ireland), D. La Forgia (Bari, Italy), A. Lancia (Pavia, Italy), D. Marčinko (Zagreb, Croatia), A. Mrkonjić (Malmö, Sweden), S. Orešković (Zagreb, Croatia), P. Ozretić (Zagreb, Croatia), S.Ž. Pavletić (Bethesda, USA), R. Pirker (Wien, Austria), B.I. Šikić (Stanford, USA), I. Tomaš (Osijek, Croatia), D. Vagić (Zagreb, Croatia), E. Vrdoljak (Split, Croatia), Ž. Vujašković (Baltimore, USA)

Indexed in SCOPUS, Index Copernicus and EMBASE/Excerpta Medica

Editorial Office:

LIBRI ONCOLOGICI, Ilica 197, 10 000 Zagreb, Croatia

Phone (385 1) 37 83 522

Web site: <http://hrcak.srce.hr/libri-oncologici>

e-mail: libri.oncologici@kbcsm.hr

The journal is published three times a year. Orders can be placed directly to the Editorial Office.

Price per copy 60 HRK. Annual subscription rates in Croatia: 300 HRK + VAT for institutions, 150 HRK + VAT for individuals and 60 HRK + VAT for students, to be remitted with Hrvatska narodna banka, account HR12 1001 0051 8630 0016 0 Ref.No.HR65 7129-051-26395 (for LIBRI ONCOLOGICI).

Annual subscription abroad - equivalent of US\$ 50 to be paid into the foreign currency account with Hrvatska narodna banka, IBAN: HR12 1001 0051 8630 0016 0 (Ref.No.HR65 7129-051-26395), BIC code: NBHRHR2XXXX (for LIBRI ONCOLOGICI)

Cover Design: Osman Berberović

Typesetting and printed by DENONA d.o.o., Zagreb

HRVATSKI
VIRTUALNI **KONGRES**
ONKOLOŠKE FARMACIJE
S MEĐUNARODNIM SUDJELOVANJEM
7. - 10. listopada 2021.
www.ccop.eu

1

CROATIAN
VIRTUAL **CONGRESS OF**
ONCOLOGY PHARMACY
WITH INTERNATIONAL PARTICIPATION
7th - 10th October 2021
www.ccop.eu

**1st CROATIAN VIRTUAL CONGRESS
OF ONCOLOGY PHARMACY**
**1. HRVATSKI VIRTUALNI KONGRES
ONKOLOŠKE FARMACIJE**

7th – 10th October 2021.
VIRTUAL CONGRESS

Supplement editor:
Robert Šeparović

Zagreb, Croatia
May, 2022

ORGANIZER

Croatian Pharmaceutical Society, Section for Oncology Pharmacy
Hrvatsko farmaceutsko društvo, Sekcija za onkološko ljekarništvo
Juraj Dobrila University of Pula
Sveučilište Jurja Dobrile u Puli

ORGANIZING COMMITTEE:

Presidents: Vesna Pavlica, Damir Vrbanec, Marko Skelin

Irena Hrستیć, Svjetlana Jakovac, Maja Koroman, Martina Kranjec Šakić, Tomislav Kukor, Klaus Meier, Ana Soldo, Martina Šepetavc, Anita Šimić, Darko Takač, Dragan Trivanović, Jurica Vrbanec, Ljiljana Vukota

SCIENTIFIC COMMITTEE:

President: Marko Skelin

Dahna Arbanas, Lidija Bach Rojecky, Natalija Dedić Plavetić, Zlatko Dembić, Eugen Javor, Robert Likić, Nataša Jovanović Lješković, Daniela Ledić Drvar, Stribor Marković, Vedrana Medeši, Leo Mršić, Anes Pašić, Stjepko Pleština, Mirjana Ptičar Canjuga, Monika Sonc, Olivera Spasovska, Robert Šeparović, Dina Šincek, Mirna Šitum, Ana Tečić Vuger, Snježana Tomić, Ljubica Vazdar, Sanda Vladimir Knežević

Contents

ORAL PRESENTATIONS

Daniela Ledić Drvar S1 - Modern diagnostic methods in the detection and follow-up of patients with malignant skin tumors	3
Daniela Ledić Drvar S2 - Clinical features and differential diagnosis of the most common malignant tumors of the skin	4
Dahna Arbanas, Jurica Vrbanec S3 - Medication errors in the treatment of pain in cancer patients	5
Andras Sule, Darija Kuruc Poje S4 - Hospital pharmacy in 21st century	6
Michael Reff, Marko Skelin S5 - The NCODA positive quality intervention (PQI): educating your medically integrated team while supporting better patient care with a concise, peer-reviewed, pharmacy-led resource	7
Maja Kuzmanović S6 - Challenges and possibilities in the prevention and treatment of febrile neutropenia in oncology patients during the COVID-19 pandemic	8
Marina Šandrk S7 - Cancer pain management	9
David Šarčević, Marko Skelin S8 - Oral anticancer medication	10
Darko Takač, Nikolina Pilić S9 - Aseptic manufacture (compounding)/ preparation of antineoplastic drugs – requirements, standards and guidelines	11
Goran Arbanas S10 - Sexual problems in patients with oncological problems: are they the consequence of a disease or of a treatment?	13
Marko Lucijanić, Petra Bistrović, Šime Manola S11 - Clinical significance of remdesivir associated bradycardia	15

Eugen Javor	
S12 - Oncology pharmacist and rationalization of resources in hospital	16
Eugen Javor	
S13 - Digital therapy in oncology	17
Mirjana Ptičar Canjuga	
S14 - Education of pharmacy technicians in oncology pharmacy	18
Kristjan Kongi	
S15 - Central preparation of cytotoxic drugs – estonian experience	19
Vesna Vugrinčić	
S16 - Role of a pharmacy technician in centralized preparation of antineoplastic agents	20
Klaus Meier	
S17 - Multiprofessional and interdisciplinarity - two sides of the same coin	21
Dražen Milković	
S18 - Impact of digital transformation on safety, quality and communication in the field on oncology pharmacy	22
Nina Dabelić, Jasmina Marić Brozić, Ana Fröbe	
S19 - The impact of patients' characteristics and disease-specific factors on the first-line treatment decisions for metastatic BRAF-mutated melanoma	23
Maja Koroman	
S20 - Professional exposure to antineoplastic drugs – toxicity classification	25
Fabrizio Festinese	
S21 - Updates in the management of chemotherapy induced nausea and vomiting	26
Nikica Mirošević Skvrce	
S22 - COVID-19 vaccines in cancer patients	27
Snježana Tomić	
S23 - ESMO guidelines for use of next generation sequencing for patients with metastatic cancers	28
Damir Vrbanec	
S24 - News in the treatment of solid tumors - ASCO, ESMO highlights	29
Martina Šepetavc	
S25 - Pharmacy technician in community pharmacy – support for oncology patients	30
Martina Šepetavc	
S26 - Pharmaceutical care for oncology patients in community pharmacy	32
Ana Tečić Vuger	
S27 - Metastatic breast cancer - chronic disease?	34

Martina Šepetavc	
S28 - Role of community pharmacist in prevention and treatment of melanoma patients	35
Martina Šepetavc	
S29 - Pharmacogenomics in community pharmacy – present or future?	37
Martina Šepetavc	
S30 - Oral antineoplastic agents in community pharmacy	39
Ana Tečić Vuger	
S31 - Immunotherapy in breast cancer	41
Mirnes Selimović	
S32 - Treatment of castration-resistant prostate cancer - new guidelines	42
Sanda Vladimir-Knežević	
S33 - The unique role of natural products in the oncology drug research and development	43
Martina Kranjec Šakić	
S34 - The application and side effects of immunotherapy - experience of Sestre milosrdnice University Hospital Center	44
Robert Šeparović	
S35 - CDK4/6 inhibitors in the treatment of breast cancer – notes for oncology pharmacist	45
Leo Mršić	
S36 - The influence of digital communication on emotions and attitudes (use of artificial intelligence for sentiment analysis and hate speech detection)	46
Vesna Pavlica, Martina Šepetavc, Tomislav Švigir, Jurica Vrbanec, Goran Arbanas, Robert Likić	
S37 - Influence of drug interactions on treatment outcomes: a case report from a pharmacy	47
Vesna Pavlica	
S38 - Precision medicine - a new development area for oncology pharmacists	49

POSTER PRESENTATIONS

Ivana Ljubičić, Nikica Mirošević Skvrce, Siniša Tomić, Ivona Bahnik Biševac	
P1 - Adverse drug reactions of ibrutinib reported to agency for medicinal products and medical devices	53
Ljubica Vazdar, Petra Linarić, Mirjana Pavlović, Ana Tečić Vuger, Robert Šeparović, Andreja Jurić	
P2 - Incidence of hypokalemia during therapy with abirateron acetate – real clinical practice data	55

Petra Linarić, Ljubica Vazdar, Ana Tečić Vuger, Mirjana Pavlović, Petra Lepetić, Robert Šeparović P3 - Thrombocytopenia induced by immune checkpoint inhibitors in triple negative breast cancer patient – case report	56
Kristina Kanceljak, Petra Lepetić, Petra Linarić, Ana Tečić Vuger, Ljubica Vazdar, Mirjana Pavlović, Robert Šeparović P4 - Management of abemaciclib side effects in clinical practice – case report	58
Biljana Grozdanovska, Nenad Mitreski, Bojana Petresk, Olivera Spasovska, Faik Misimi P5 - A single institutional experience with cetuximab in metastatic colorectal cancer	60
Anni Mikić P6 - Elements of quality assurance in the preparation of antineoplastic drugs in hospital pharmacies	61
Sanda Vladimir-Knežević, Biljana Blažeković, Maja Bival Štefan, Marija Kindl, Mateja Mervić P7 - New insights into the potential use of medical cannabis in cancer care	63
Petra Lepetić, Petra Linarić, Dejana Jezernik, Kristina Kanceljak, Ana Tečić Vuger, Mirjana Pavlović, Ljubica Vazdar, Robert Šeparović P8 - Nivolumab induced hypopituitarism – case report	64
AUTHOR INDEX	65